Does family history of metabolic syndrome affect the metabolic profile phenotype in young healthy individuals?

Diabetology and Metabolic Syndrome

Volumn 6, Issue 1, 2014, Pages

  Lipińska, Anna ^a   Koczaj Bremer, Magdalena ^a   Jankowski, Krzysztof ^a   Kaźmierczak, Agnieszka ^a   Ciurzyński, Michał ^a   Ou Pokrzewińska, Aisha ^a   Mikocka, Ewelina ^a   Lewandowski, Zbigniew ^a   Demkow, Urszula ^a   Pruszczyk, Piotr ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Cardiovascular disease; Family history; Metabolic syndrome; Risk factors

Indexed keywords

CHOLESTEROL; GLUCOSE; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NON HIGH DENSITY LIPOPROTEIN CHOLESTEROL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; FAMILY HISTORY; FEEDING BEHAVIOR; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; METABOLIC SYNDROME X; OBESITY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE;

EID: 84902902079     PISSN: None     EISSN: 17585996     Source Type: Journal    
DOI: 10.1186/1758-5996-6-75     Document Type: Article

References (27)

1. SIGN (Scottish Intercollegiate Guidelines Network). Risk Estimation and the Prevention of Cardiovascular Disease. A National Clinical Guideline.2007. Report No 97. [ http://www.sign.ac.uk/guidelines ]
2. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10 year results from 37 WHO MONICA Project populations. Tunstall-Pedoe H, Kuulasmaa K, Mähönen M, Tolonen H, Ruokokoski E, Amouyel P, for the WHO MONICA (monitoring trends and determinants in cardiovascular disease) Project, Lancet 1999 353 1547 1557
3. World Health Organization. Joint WHO/FAO Expert Consultation on Diet, Nutrition, and the Prevention of Chronic Diseases. 2002 Report No. 916. [ http://www.who.int/dietphysicalactivity/publications ]
4. Family history of coronary heart disease and markers of subclinical cardiovascular disease: Where do we stand? Pandey AK, Pandey S, Blaha MJ, Agatston A, Feldman T, Ozner M, Santos RD, Budoff MJ, Blumenthal RS, Nasir K, Atherosclerosis 2013 228 285 294
5. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and other Societies on Cardiovascular Disease Prevention in Clinical Practice. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, Albus C, Benlian P, Boysen G, Cifkova R, Deaton C, Ebrahim S, Fisher M, Germano G, Hobbs R, Hoes A, Karadeniz S, Mezzani A, Prescott E, Ryden L, Scherer M, Syränne M, op Reimer WJ S, Vrints C, Wood D, Zamorano JL, Zannad F, Eur Heart J 2012 33 1635 1702
6. Metabolic syndrome and risk of incident cardiovascular events and death. A systematic review and meta-analysis of longitudinal studies. Gami AS, Witt BJ, Howard DE, Erwin PJ, Gami LA, Somers VK, Montori VM, JACC 2007 49 403 414
7. Trend in the prevalence of the metabolic syndrome and its impact on cardiovascular disease incidence: the San Antonio Heart Study. Lorenzo C, Williams K, HuntK J, Haffner SM, Diabetes Care 2006 29 625 630
8. Prevalence of the metabolic syndrome and its relation to all- cause and cardiovascular mortality in nondiabetic European men and women. Hu G, Qiao Q, Tuomilehto J, Balkan B, Borch-Johnsen K, Pyorala K, Arch Intern Med 2004 164 1066 1076
9. The metabolic syndrome. Prevalence and associated risk factor findings in the US population from the Third National Health and Nutritional Examination Survey, 1988-1994. Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon M, Heymsfield SB, Arch Intern Med 2003 163 427 436
10. Incidence of metabolic syndrome over 9 years follow-up; the importance of sex differences in the role of insulin resistance and other risk factors. Hadaegh F, Hasheminia M, Lotfaliany M, Mohebi R, Azizi F, Tohidi M, PLoS One 2013 8 9 76304
11. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on scientific issues related to management. Grudy SM, Brewer HB Jr, Cleeman JI, Smith SC, Lenfant C Jr, Circulation 2004 109 433 438
12. Harmonizing the metabolic syndrome: a Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Hear, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Society; and International Association for the Study of Obesity. Alberti KGMM, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JCH, James WPTJ, Loria CM, Smith SC, Circulation 2009 120 1640 1645
13. Clinical evaluation of adult treatment panel III criteria in identifying insulin resistance with dyslipidemia. Liayo Y, Kwon S, Shaughnessy S, Wallace P, Hutto A, Jenkins AJ, Klein RL, Garvey WT, Diabets Care 2004 27 978 983
14. The metabolic syndrome: requiescat in pace. Reaven GM, Clin Chem 2005 51 931 938
15. Homeostasis model assessment: insulin resistance and b-cell function from fasting plasma glucose and insulin concentration in men. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC, Diabetologia 1989 28 412 419
16. Reliability of dietary guestionnaire on food habits, eating behaviour and nutritional knowledge of adolescents. Turconi G, Celsa M, Rezzani C, Biino G, Sartirana MA, Roggi C, Eur J Clin Nutr 2003 57 573 763
17. International Physical Activity Questionnaire IPAQ. [ http://www.ipaq.ki.se ]
18. General and abdominal adiposity and risk of death in Europe. Pischon T, Boeing H, Hoffman K, Bergmam M, Schulze MB, Overvad K, van der Schouw YT, Spencer E, Moons KGM, Tjønneland A, Halkjaer J, Jensen MK, Stegger J, Clavel-Chapelon F, Boutron-Ruault M-C, Chajes V, Linseisen J, Kaaks R, Trichopoulon A, Trichopoulos D, Bamia C, Sieri S, Palli D, Tumino R, Vineis P, Panico S, Peeters PHM, May AM, Bueno-de-Mesquita HB, van Duijnhoven FJB, et al. N Eng J Med 2008 359 2105 2120
19. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Yusuf S, Hawken S, Ôunpuu S, Bautista L, Franzosi MG, Commerford P, Lang CC, Rumboldt Z, Onen CL, Lisheng L, Tanomsup S, Wangai P Jr, Razak F, Sharma AM, Anand SS, Lancet 2005 366 1640 1649
20. Serum cholesterol level mortality findings for men screened in the Multiple Risk Factor Intervention Trial. Multiple Risk Factor Intervention Trial Research Group. Neaton JD, Blackburn H, Jacobs D, Kuller L, Lee D-J, Sherwin R, Shih J, Stamler J, Wentworth D, Arch Intern Med 1992 152 1490 1500
21. Meta-analysis of the relationship between non-high density lipoprotein cholesterol reduction and coronary heart disease risk. Robinson JG, Wang S, Smith BJ, Jacobson TA, J Am Coll Cardiol 2009 53 316 322
22. Insulin and cardiovascular disease: biomarker or association? Jandeleit-Dahm KAM, Gray SP, Diabetologia 2012 55 3145 3151
23. Inflammatory cytokines impair endothelium-dependent dilatation in human veins in vivo. Bhagat K, Vallance P, Circulation 1997 96 3042 3047
24. Body mass index and prevalence of hypertension and dyslipidemia. Brown CD, Higgins M, Donato KA, Rohde FC, Garrison R, Obarzanek E, Horan M, Obesity Res 2000 8 605 619
25. Association between the metabolic syndrome and parental history of premature cardiovascular disease. Dallongeville J, Grupposo MC, Cottel D, Ferrieres J, Arveiler D, Bingham A, Ruidavets JB, Haas B, Ducimetière P, Amouyel P, Eur Heart J 2006 27 722 728
26. Familial History of Metabolic Disorders and the Multiple Metabolic Syndrome: The NHLBI Family Heart Study. Hunt KJ, Heiss G, Sholinsky PD, Province MA, and the FHS Investigators, Genet Epidemiol 2000 19 395 409
27. Metabolic syndrome and insulin resistance in normal glucose tolerant Brazilian Adolescents with family history of type 2 diabetes. da Silva RC, Miranda WL, Chacra AR, Dib SA, Diabetes Care 2005 3 716 718